All In Biotech

Drug Trial Radar · NCT03519386

Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%

Prospective, Randomized Phase III Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%

Last checked: Nov 19, 2026Latest source record: Nov 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 590 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

590

Actual

Start

Jul 26, 2018

Primary completion

Apr 5, 2022

Study completion Apr 2, 2024

Sponsor

Lead sponsor
Glaukos CorporationIndustry
Sponsor type
Industry
First posted
May 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase III study to compare the safety and efficacy of intraocular implants containing travoprost at two different elution rates versus Timolol Maleate Ophthalmic Solution, 0.5% (timolol) in reducing elevated intraocular pressure in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Conditions

  • Glaucoma, Open-Angle
  • Ocular Hypertension

Interventions

  • G2-TR intraocular implant containing travoprostCombination product

    Provided in Arm/Group descriptions.

  • Sham surgery + active-comparator eye dropsDrug

    Sham surgery plus postoperative active-comparator eye drops (timolol maleate ophthalmic solution, 0.5%).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Diurnal IOP (as Measured at 8AM and 10AM) Through 3 Months PostoperativeTime frame: 3 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Vance Thompson Vision

    Sioux Falls, South Dakota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.